Indications for Mechanical Thrombectomy-Too Wide or Too Narrow?


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 24 02 2019
revised: 10 04 2019
accepted: 11 04 2019
pubmed: 23 4 2019
medline: 21 1 2020
entrez: 23 4 2019
Statut: ppublish

Résumé

The indications for mechanical thrombectomy (MT) have expanded since the American Heart Association/American Stroke Association reported its first guidelines for MT in 2013. Multiple subsequent randomized clinical trials of MT have proved its efficacy, including the DAWN (DWI [diffusion weighted imaging] or CTP [computed tomography perfusion] Assessment with Clinical Mismatch in the Triage of Wake-up and Late Presenting Strokes Undergoing Neurointervention with Trevo) and DEFUSE-3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke-3) trials. The current guidelines from the American Heart Association/American Stroke Association provide class I support for the use of MT for the following indications: 1) internal carotid artery (ICA)/M1 middle cerebral artery (MCA) occlusion, symptom onset <6 hours, National Institutes of Health Stroke Scale score of ≥6, Alberta Stroke Program Early Computed Tomography Score of ≥6; and 2) large vessel occlusions in the anterior circulation, symptom onset 6-16 hours, and meeting the DAWN or DEFUSE-3 eligibility criteria. Class IIa evidence is also available for the use of MT for large vessel occlusions in the anterior circulation, symptom onset 16-24 hours, and meeting other DAWN eligibility criteria. In clinical practice, these class I and IIa indications for MT have been well followed. However, many other potential indications are available, including 1) M2 or M3 MCA occlusion, symptom onset <6 hours; 2) Alberta Stroke Program Early Computed Tomography Score <6, ICA or M1 MCA occlusion, symptom onset <6 hours; 3) National Institutes of Health Stroke Scale score <6, ICA or M1 occlusion, symptom onset <6 hours; 4) tandem occlusions; and 5) posterior circulation occlusion <6 hours. The present review analyzed the available data to provide support for further prospective clinical trials regarding these potential indications.

Identifiants

pubmed: 31009772
pii: S1878-8750(19)31110-6
doi: 10.1016/j.wneu.2019.04.116
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

492-499

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Zeguang Ren (Z)

Department of Neurosurgery, University of South Florida, Tampa, Florida, USA; Center for Cerebrovascular Diseases, Taihe Hospital, Shiyan, Hubei, China. Electronic address: renzem@gmail.com.

Maxim Mokin (M)

Department of Neurosurgery, University of South Florida, Tampa, Florida, USA.

Clayton T Bauer (CT)

Department of Neurosurgery, University of South Florida, Tampa, Florida, USA.

Zhongrong Miao (Z)

Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

W Scott Burgin (WS)

Department of Neurology, University of South Florida, Tampa, Florida, USA.

Yongjun Wang (Y)

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH